ATAnna M. Titova

Anna M. Titova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna M. Titova has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MSCT and MRI indicators for assessing iron overload and the effectiveness of iron overload therapy in patients with primary and secondary hemochromatoses

    by A. M. Titova, V. A. Fokin, G. E. Trufanov, M. A. Zubkov, A. V. Nikitina, R. R. Mironchuk, M. V. Mironchuk, N. V. Tsvetkova, K. S. Shalygina, L. E. Galyautdinova, et al.

    Goal of research. Evaluation of MRI, CT parameters after chelation and hemoexfusion therapy in patients with iron overload, identification of the prognostic value of CT indicators in the assessment of moderate and severe iron overload. Materials and methods. The design of the study is prospective. The study included 43 patients with hereditary hemochromatosis (HH), secondary transfusion-dependent hemochromatosis (TDH) receiving regular hemotransfusions, iron chelators. We evaluated age, frequency of hemotransfusions, chelating drug used. CT was performed on a two-energy computer tomograph Siemens Somatom Definition 128. 27 patients (62.8%) reached repeated CT. MRI was performed on a Siemens Magnetom Espee high-field tomograph with a magnetic field induction of 1.5 T. Results. The median age was 34.00 [33.00; 53.50] for HH and 52 [36.00; 62.00] for TDH. After therapy in the general group, T2* values increased by 26%, LIC decreased by 21.2%, DEDHU 140 and 80 mean by 17.6%, DERHU 140 and 80 mean by 3%, DEIHU 140 and 80 mean by 92.8%, 80 max by 3%, DEDHU 140 and 80 max by 19%, DERHU 140 and 80 max by 2.5% after therapy. In patients with HH, liver T2* increased by 4.6 times, LIC decreased by 5.5 times, DEDHU 140 and 80 mean by 35.1%, DERHU 140 and 80 mean by 7.8%, DEIHU 140 and 80 mean by 93.6%, DEDHU 140 and 80 max by 29.3%, DEIHU 140 and 80 max by 21.6%. In patients with TDH, LIC decreased by 18.9%, DEIHU 140 and 80 mean by 92.2%. A value of 80 mean ≥ 85.5, 140 mean ≥ 71.5, M0.3 mean ≥ 76, DEIHU 140 and 80 mean ≥ 0.007996 and DEDHU 140 and 80 mean ≥ 18.5 predict the probability of severe iron overload. Conclusion. In patients after chelation therapy and hemoexfusion therapy, MRI and CT indicators decrease. The values of CT 80 mean ≥ 85.5, 140 mean ≥ 71.5, M0.3 mean ≥ 76, DEIHU 140 and 80 mean ≥ 0.007996, DEDHU 140 and 80 mean ≥ 18.5 can predict LIC values of more than 11 mg/g.

  • MRI for Quantitative Determination of Iron in the Liver and Heart in Patients with Primary and Secondary Hemochromatoses in Association with Serrum Ferritin: Single-Stage Observational Study

    by Anna M. Titova, Vladimir A. Fokin, Gennadii E. Trufanov, Ksenia S. Shalygina, Nadezhda V. Tsvetkova

    Background. An extremely small number of studies have been devoted to the study of differences in LIC (liver iron concentration) and MIC (myocardium iron concentration) indicators, as well as their correlation with each other and with ferritin levels in patients with various nosological forms. Aims to study the relationship of ferritin, LIC and MIC levels in patients with various causes of hemochromatosis (hereditary hemochromatosis (HH), aplastic anemia (AA), primary myelofibrosis (PMF), thalassemia (TL), myelodysplastic syndrome (MDS)). Methods. The design of the study is a singlestage observational one. The study included 91 patients with primary hemochromatosis and secondary transfusion-dependent hemochromatosis receiving regular blood transfusion and iron chelate therapy from 2015 to 2018. The studies were carried out on 1.5 T MR-scanner Magnetom Espree (Siemens, Germany), and myocardial iron concentration (MIC) was calculated using the formula MIC = 45 (T2*) 1.22. Liver iron concentration (LIC) was calculated using the formula LIC = 0.03 R2* + 0.74. The ferritin level was determined by enzyme immunoassay. Statistical processing of the results obtained was carried out using the SPSS software package. Results. Connections between LIC and ferritin (r = 0.867; p 0.001), MIC and ferritin (r = 0.759; p = 0.004) and LIC and MIC (r = 0.737; p = 0.006) were found in patients with primary hemochromatosis, while in patients with secondary hemochromatosis significant correlations were found only between LIC and MIC (r = 0.503; p 0.001), while the relationship was average. Links between LIC and ferritin were found in patients with AA (r = 0.656; p = 0.040), an average relationship, in patients with TL (r = 0.714; p = 0.020), an average relationship. The relationship between MIC and ferritin was revealed in patients with AA (r = 0.703; p = 0.050), an average relationship, in patients with TL (r = 0.757; p = 0.018), an average relationship. At the same time, in patients with MDS and PMF in this study, there was no association between ferritin and LIC, ferritin and MIC. Conclusions. In patients with hereditary hemochromatosis, LIC and MIC are associated with ferritin, and MIC is also associated with LIC (medium bond). In patients with iron overload due to thalassemia, an average correlation between LIC and ferritin, MIC and ferritin was revealed. In patients with iron overload due to aplastic anemia, an average correlation between LIC and ferritin, MIC and ferritin was revealed.